SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

@article{Kimura2021SARSCoV2LV,
  title={SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance},
  author={Izumi Kimura and Yusuke Kosugi and Jiaqi Wu and Daichi Yamasoba and Erika P Butlertanaka and Yurie Tanaka and Yafei Liu and Kotaro Shirakawa and Yasuhiro Kazuma and Ryosuke Nomura and Yoshihito Horisawa and Kenzo Tokunaga and Akifumi Takaori-Kondo and Hisashi Arase and Akatsuki Saito and So Nakagawa and Kei Sato},
  journal={bioRxiv},
  year={2021}
}
SARS-CoV-2 Lambda, a new variant of interest, is now spreading in some South American countries; however, its virological features and evolutionary trait remain unknown. Here we reveal that the spike protein of the Lambda variant is more infectious and it is attributed to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion mutation in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies. Since the… 
Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
TLDR
The reduced neutralization ability of the Lambda variant suggests that the efficacy of monoclonal antibodies and vaccines may be compromised during the current pandemic.
Increased resistance of SARS-CoV-2 Lambda variant to antibody neutralization
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
TLDR
The data suggest that the P681R mutation is a hallmark of the virological phenotype of the B.1.617.2/Delta variant and is associated with enhanced pathogenicity, which is highly fusogenic and notably more pathogenic than prototypic SARS-CoV-2 in infected hamsters.
Severity, Pathogenicity and Transmissibility of Delta and Lambda Variants of SARS-CoV-2, Toxicity of Spike Protein and Possibilities for Future Prevention of COVID-19
TLDR
Delta and Lambda variants demonstrate high infectivity and are less responsive to the immune response in vaccinated individuals, and future therapeutic strategies are discussed, including those based on high stability of epitopes, conservation of the N protein and the novel intracellular antibody receptor, tripartite-motif protein 21 (TRIM21) recognized by antibodies against the Nprotein.
The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines
TLDR
It is found that sera from Pfizer-BioNTech vaccine remain high reactivity toward the receptor binding domain (RBD) of Delta variant while it drops dramatically toward that of Lambda variant, which could be one of major reasons for breakthrough infections.
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
TLDR
This work generates fusion proteins composed of the extracellular portions of ACE2 and RBD fused to the Fc portion of human IgG1 that demonstrate that ACE2-Ig is enzymatically active and that it can be recognized by the SARS-CoV-2 RBD, independently of its enzymatic activity.
Predicting spike protein NTD mutations of SARS-CoV-2 causing immune escape by molecular dynamics simulations
TLDR
Investigating critical residues for NTD-antibody bindings and their detailed mechanism showed that some residues on NTD including Y144, K147, R246 and Y248 are critically involved in the direct interaction of NTD with many monoclonal antibodies (mAbs), indicating that the viruses harboring these residue mutations may have high risk of immune evasion.
B.1.617.3 SARS CoV-2 spike E156G/Δ157-158 mutations contribute to reduced neutralization sensitivity and increased infectivity
TLDR
It is revealed that N-terminal domain (NTD)-specific E156G/Δ157-158 contributed to increased infectivity and reduced sensitivity to ChAdOx1 nCoV-19 vaccine (Covishield™)-elicited neutralizing antibodies.
Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant
TLDR
Bioinformatics analysis suggests that a combination of shortening the immunogenic epitope loops and the generation of potential N-glycosylation sites may be a viable adaptation strategy, potentially allowing this emerging viral variant to escape from host immunity.
SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19
TLDR
This work evaluated the effects of monoclonal antibodies, convalescent serum, and vaccines on Delta variant, which leads to concerns about the effectiveness of current vaccines to the upcoming SARS-CoV-2 variants, and found that one dose of BNT162b2 vaccination after natural infection could provide effective protection against variant Alpha, Beta, and Delta.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
An Emerging SARS-CoV-2 Mutant Evades Cellular Immunity and Increases Infectivity
TLDR
It is demonstrated that two recently emerging mutations in the receptor - binding domain of the SARS-CoV-2 spike protein, L452R and Y453F, confer escape from HLA-A24-restricted cellular immunity.
Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity
TLDR
Cryo-EM structural analyses revealed allosteric effects of the mutations on spike conformations and revealed mechanistic differences that either drive inter-species transmission or promotes viral escape from dominant neutralizing epitopes.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
TLDR
The recent emergence of new SARS-CoV-2 variants B.1.2.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
TLDR
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage, and new variants with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.
TLDR
The recent emergence of new SARS-CoV-2 variants B.2.1.351 and emergent variants13,14 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
TLDR
As antibodies binding to spike receptor-binding domain and N-terminal domain demonstrate diminished neutralization potency in vitro against some emerging variants, updated mAb cocktails targeting highly conserved regions, enhancement of mAb potency or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.
...
1
2
3
4
5
...